BioNTech SE Q3 FY2026 earnings call

• Leadership Transition: Co-founders Ugur Sahin and Ozlem Tureci announced their departure, with Guido Oelkers set to become CEO by February 1st, 2027. The founders will remain as shareholders.
• Oncology Pipeline Progress:
  • Gotistobar: Updated data showed median overall survival of 18.5 months vs. 10 months for chemotherapy in squamous NSCLC (HR 0.56). Pivotal trial interim analysis expected before year-end.
  • Pumitamic: Entered pivotal stage in TNBC with Gilead (replacing chemo with ADC). Strong combination data with LVD in small cell lung cancer (92% ORR in first-line).
  • TPAM: Met primary endpoint in HR+/HER2-low metastatic breast cancer but faced safety concerns (ILD). Discussions ongoing with Duality Bio regarding BLA submission.
• Strategic Shifts: Discontinued phase 2 autogene cevumeran trial in colorectal cancer due to OS imbalance. BNT113 head and neck cancer trial continues despite missing PFS endpoint, awaiting OS readout.
• Financial Discipline: Divested JPT Peptide Technologies. Integrating InstaDeep AI capabilities into core business. Share buybacks continued ($5 million shares repurchased since June). Cash position strong at $16.2 billion.

Revenue for the third quarter of 2026 was €1.3 billion, a decline from €1.5 billion in the prior year period, primarily due to lower demand for the COVID-19 vaccine. Revenue recognized from the partnership with VMS (Valneva) related to Pumitami was €613 million. Year-to-date revenues were $1.5 billion compared to $2 billion in the prior year period. The transcript does not provide specific revenue contribution percentages for individual product segments.

• Revenue: Raised full-year 2026 revenue guidance midpoint to $1.7–$1.9 billion.
• Expenses: Adjusted R&D expense guidance remains unchanged at $2–$2.3 billion. SG&A expense guidance remains unchanged at $700–$800 million.
• Outlook: Management emphasized that 2027 financial details are premature to discuss but highlighted the transition to royalty-based economics with Genentech/Roche to improve financial structure without affecting clinical progress.

• Clinical Trial Failures/Discontinuations: Discontinuation of autogene cevumeran in colorectal cancer; BNT113 missed PFS endpoint in head and neck cancer.
• Safety Signals: Higher rate of interstitial lung disease (ILD) reported in TPAM trials, including severe/fatal events, raising questions about benefit-risk profile in HR+/HER2-low breast cancer.
• Regulatory Uncertainty: Gotistobar’s pivotal trial outcome depends on upcoming interim analysis; potential delays or changes in regulatory expectations.
• Market Competition: Evolving standard of care in TNBC and other indications requires rapid adaptation of trial designs (e.g., switching from chemo to ADCs in Rosetta Breast 01).

Q: Analyst asked if management is more confident in hitting the first or second interim for Gotistobar and how mRNA/cancer vaccines fit into future strategy given the Roche collaboration changes. / A: Ozlem Tureci noted the first interim this year is early and they won't be disappointed if no clear signal appears, though excited by prior data. Ramon Zapata clarified that changing Genentech collaboration terms to royalty-based economics is a resource allocation decision to fund other priorities, not a lack of commitment to mRNA. They remain focused on advancing mRNA programs like PDAC and BNT113.

Q: Analyst asked about the status of BioNTech's own TROP2 ADC and how it compares to other ADCs in combination with Pumitamic across different tumor types. / A: Ozlem Tureci stated they view their ADC portfolio as a broad design space, comparing multiple targeted ADCs (including TROP2) for clinical benefit with Pumitamic rather than committing to one. Annemarie Hanekamp added that Pumitamic is intended to be the backbone of combinations, working with both internal assets and partners' ADCs, with decisions driven by emerging data.

Q: Analyst questioned why BioNTech exercised an option to shift Genentech collaboration costs to royalty-based economics despite a strong balance sheet, and if this gives Genentech more influence. / A: Ramon Zapata explained the move provides financial flexibility to allocate resources to other high-value pipeline priorities. He confirmed existing agreements remain in place and clinical progress continues unaffected. The change optimizes the financial structure without altering development pace or indication selection control.

Q: Analyst asked about enrollment progress for Pumitamic Phase 3 trials and commercial opportunity for Gotistobar in second-line squamous NSCLC. / A: Ozlem Tureci outlined seven global pivotal studies ending in 2027-2029, noting timing is event-driven. Annemarie Hanekamp estimated ~55,000 patients in G7 second-line squamous NSCLC by 2030, viewing Gotistobar as a key asset contributing to multi-product company goals. They would comment on interim results if IDMC recommends continuation.

Q: Analyst sought clarity on criteria for advancing Pumitamic+ADC combinations and impact of recent data on conviction levels. / A: Annemarie Hanekamp emphasized a data-driven approach, monitoring safety and efficacy across various ADC partners and internal assets. They prioritize lung, breast, GI, and GU cancers, ensuring combinations address evolving unmet needs. Decisions on which candidates advance will be based on total data packages released in 2027 milestones.